Abstract:e15516 Background: Peritoneal metastasis (PM) is the most frequent mode of distant metastasis in advanced gastric cancer (GC). Most PM could cause peritoneal effusion. However, the cytological examination of cancer cells in peritoneal effusion is less sensitive to the identification of PM early; the specificity of serum biomarkers in peritoneal effusion is poor. It is necessary to assess the feasibility of peritoneal effusion circulating tumor DNA (ctDNA) for the PM diagnosis. Methods: 22 GCs with clinically confirmed PM as positive subjects and 11 non-cancers without PM as negative control were recruited. GC tissues were collected from 16 positive subjects. Peritoneal effusion supernatant (AS), peritoneal effusion cells (AC), and plasma were collected from each subject. Next generation sequencing (NGS) was performed using a 1021-gene panel. Sensitivity and specificity for the diagnosis of GC with PM were assessed. Results: Median age of 22 GCs with PM was 57 yrs. 12 patients were male. Diffused and mixed-type accounted for 73%. For 45% of patients, primary tumor was found in gastric body. In tissue samples, recurrent genes were TP53 (63%), CDH1 (50%), RHOA (19%), TGFBR1 (19%), KRAS (13%), and PIK3CA (13%). Private and tumor-derived mutations were found in the AS, AC, and plasma. 95% of (21/22), 82% (18/22), and 77% (17/22) of AS, AC, and plasma samples carried mutations, respectively. AS had more mutations than AC and plasma (Wilcoxon’s matched-pairs signed-ranked test, AS vs AC, p= 0.006; AS vs plasma, p = 0.013). 98% of the AC and 80% plasma mutations were contained in AS, Variant allele frequency (VAF) in AS was higher than others (Mann Whitney test, AS vs AC, p= 0.038; AS vs plasma, p< 0.001). In 22 GCs with PM, 3 were identified with no cancer cells in AS using cytological examination. Of these, 3 were detected with mutations in AS, one with mutations in AC. Mutations were detected in only one negative control AS and AC. Receiver operating characteristic (ROC) curve showed the number of mutations was related to PM (AS: AUC 0.93, 95% CI 0.82-1.00, p< 0.001; AC: AUC 0.85, 95% CI 0.70-1.00, p= 0.001). When the threshold was determined with one mutation, the sensitivity and specificity were 95% and 91% in AS, 82% and 91% in AC, respectively. Conclusions: Peritoneal effusion ctDNA contained tumor-derived and specific mutations. Peritoneal effusion ctDNA can be used for the auxiliary diagnosis of PM.

Detection of genes related to peritoneal metastasis of primary gastric cancer based on large-panel Next Generation Sequencing.

Oncogenic aberrations in primary gastric cancer tumors to predict metachronous peritoneal metastasis.

Erratum: Whole Genome and Transcriptome Sequencing of Matched Primary and Peritoneal Metastatic Gastric Carcinoma

Genetic specificity study using next-generation sequencing (NGS) of peritoneal metastatic colorectal cancer compared to primary colorectal cancer

Identification of Metabolism-Related Genes for Predicting Peritoneal Metastasis in Patients with Gastric Cancer

The Ctdna in Peritoneal Effusion of Advanced Gastric Cancer for Auxiliary Diagnosis of Peritoneal Metastasis.

Predicting Peritoneal Dissemination Of Gastric Cancer In The Era Of Precision Medicine: Molecular Characterization And Biomarkers

Identification and Validation of Crucial Lnc-Trim28-14 and Hub Genes Promoting Gastric Cancer Peritoneal Metastasis

Utility Of Circulating Tumor Dna In Genomic Profiling Of Colorectal Cancer With Peritoneal Metastasis.

Differential Gene Expression Profiles of Gastric Cancer Cells with High Metastatic Potential to Peritoneum

Effectiveness of peritoneal lavage fluid circulating tumour cells and circulating tumour DNA in the prediction of metachronous peritoneal metastasis of gastric cancer (pT4NxM0/pT1-3N+M0) after radical resection: protocol of a prospective single-centre clinical study

Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases

[Diagnostic methods for peritoneal molecular residual disease in gastric cancer]

Circulating exosomal microRNA signature to predict peritoneal metastasis in patients with advanced gastric cancer.

Transcriptomics-based liquid biopsy panel for early non-invasive identification of peritoneal recurrence and micrometastasis in locally advanced gastric cancer

Comprehensive Analysis of Peritoneal Metastasis Sequencing Data to Identify LINC00924 As a Prognostic Biomarker in Gastric Cancer

Genomic characterization of Chinese locally advanced or metastatic gastric cancer.

Detection of a Novel Panel of 24 Genes with High Frequencies of Mutation in Gastric Cancer Based on Next-Generation Sequencing.

Exosomal hsa-let-7g-3p and hsa-miR-10395-3p derived from peritoneal lavage predict peritoneal metastasis and the efficacy of neoadjuvant intraperitoneal and systemic chemotherapy in patients with gastric cancer

Identification of Key Genes and Signaling Pathways Associated with the Progression of Gastric Cancer

TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer